LONDON/COPENHAGEN, May 7 (Reuters) - Novo Nordisk's head

of U.S. operations said on Wednesday the company fully expects

the U.S. Food and Drug Administration to enforce a ban on

compounded copies of Wegovy and Ozempic when it comes into force

on May 22.

"At that time, we will continue to fight against unlawful

compounding," said David Moore, the company's executive vice

president of U.S. operations, on an analyst call following the

release of first-quarter results.